| Symbol | ADXN |
|---|---|
| Name | ADDEX THERAPEUTICS LTD. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Pharmaceutical Preparations |
| Address | CHEMIN DES MINES 9, GENEVA, V8 CH-1202 |
| Telephone | 01141228841555 |
| Fax | — |
| — | |
| Website | https://www.addextherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001574232 |
| Description | Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The companys geographical area of operations includes Switzerland and Europe. Additional info from NASDAQ: |
Teyssedou Lenaic Nathanael 🟡 adjusted position in 0 shares (16 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.16 Transaction Date: Sep 02, 2026 | Filing ID: 105509
Read moreKalinichev Mikhail 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105506
Read moreDirector Nunn Jason Raleigh 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105501
Read moreDirector Mills Roger 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105496
Read moreDirector Manke Isaac 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105491
Read moreDirector Lawton Vincent Michael 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105489
Read moreDirector Hill Raymond George 🟡 adjusted position in 0 shares (2 derivative) of Addex Therapeutics Ltd. (ADXN) at $0.06 Transaction Date: Sep 02, 2026 | Filing ID: 105484
Read moreNew Form SCHEDULE 13D/A - Addex Therapeutics Ltd. <b>Filed:</b> 2026-08-27 <b>AccNo:</b> 0001104659-26-101798 <b>Size:</b> 17 KB
Read moreADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Read moreAddex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Read more